Relmada Expects Its $202.1 Million Cash Base To Fund Trials And Operations Through 2029

Early bladder-cancer follow-up showed lasting responses, but two patients progressed to muscle-invasive disease.

Share
Relmada Expects Its $202.1 Million Cash Base To Fund Trials And Operations Through 2029

Relmada Therapeutics, which is testing bladder-cancer treatment NDV-01, expects approximately $202.1 million in cash and short-term investments to cover operations through 2029, including both pivotal bladder-cancer study groups. The company released the preliminary, unaudited third-quarter results Thursday alongside an SEC filing.

Longer Responses, With Progression In Two Patients

The initial, preliminary extension results showed that 12 of 14 evaluable patients who had no detectable cancer at 12 months still had complete responses at 18 months—86%. Of 23 patients entering extended follow-up, 14 had reached the 18-month assessment.

Among patients whose disease had not responded to BCG, a bladder-cancer treatment, seven of eight evaluable patients retained complete responses at 18 months, or 88%. Eleven patients in that subgroup entered the extension.

Two patients who had not previously received BCG developed muscle-invasive cancer at the 15-month assessment. Through 12 months, no patients had progressed or undergone bladder removal; the company's updated presentation showed no bladder removals through 18 months.

The updated core study included 51 evaluable patients. Complete responses occurred at some point in 48 patients, or 94%; at 12 months, 24 of 31 evaluable patients had complete responses, or 77%. The BCG-unresponsive subgroup's corresponding rates were 96% and 73%.

No severe treatment-related adverse events, treatment-related serious events or treatment-related discontinuations were reported. Treatment-related side effects nevertheless occurred in 35 of 51 patients, or 69%, including uncomfortable urination, blood in urine and urinary urgency or frequency.

Cash Backing For SPECTRUM

Relmada has no approved products and has not generated revenue. NDV-01 combines gemcitabine and docetaxel in a controlled-release treatment delivered into the bladder for cancer that has not invaded the bladder muscle.

The company targets year-end 2026 applications seeking FDA permission to begin trials of NDV-01 and sepranolone. It expects the late-stage SPECTRUM bladder-cancer program and a mid-stage sepranolone study in Prader-Willi syndrome to start after clearance. Sepranolone's pre-filled syringe is undergoing final stability testing.

SPECTRUM, renamed from RESCUE, retains its two independent paths toward potential approval. One studies high-risk patients whose disease failed prior treatments; the other compares NDV-01 with observation after tumor removal in intermediate-risk patients. A separate exploratory group is not intended to support approval. Trial sites are preparing for enrollment.

Relmada Chief Executive Officer Sergio Traversa said the company has a manufacturing plan to provide "uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program."

Research Spending Rises, Administration Falls

First-quarter stock issuance brought in $150.4 million in net proceeds. Cash and short-term investments stood at approximately $93.0 million at year-end 2025.

Third-quarter research spending rose by $5.2 million to $9.2 million from $4.0 million a year earlier. Relmada attributed the increase mainly to study preparation, manufacturing, storage and employee pay, partly offset by lower stock-based compensation.

Administrative spending fell by approximately $2.4 million to $3.9 million from $6.3 million. The company attributed the decline chiefly to lower stock-based compensation and stock appreciation rights expense, partly offset by higher employee pay and consulting costs.

Quarterly operating cash use rose to $12.6 million from $6.7 million. Net loss widened to $13.9 million from $10.1 million, while loss per share narrowed to $0.12 from $0.30.

For the first nine months, research spending reached $25.7 million versus $18.8 million, and administrative spending totaled $21.9 million versus $20.0 million. Operating cash use was $37.3 million versus $31.2 million; net loss was $45.8 million, or $0.44 per share, versus $37.5 million, or $1.16 per share.

Relmada's funding forecast includes completion of both pivotal SPECTRUM groups; their launch remains dependent on FDA clearance of the planned trial application.

Sources